	US 11,833,176 B2
	Composition for treating neonatal HIE
Yun Sil Chang, Seoul (KR); Won Soon Park, Seoul (KR); So Yoon Ahn, Seoul (KR); and Dong Kyung Sung, Seoul (KR)
Assigned to MEDINNO INC., Gyeonggido-do (KR)
Appl. No. 16/478,330
Filed by MEDINNO INC., Gyeonggido-do (KR)
PCT Filed Oct. 31, 2017, PCT No. PCT/KR2017/012119 § 371(c)(1), (2) Date Jul. 16, 2019, PCT Pub. No. WO2018/131779, PCT Pub. Date Jul. 19, 2018.
Claims priority of application No. 10-2017-0007355 (KR), filed on Jan. 16, 2017; and application No. 10-2017-0142236 (KR), filed on Oct. 30, 2017.
Prior Publication US 2019/0374581 A1, Dec. 12, 2019
Int. Cl. A61K 35/28 (2015.01); A61K 35/51 (2015.01); A61P 25/28 (2006.01); C12N 5/0775 (2010.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 35/50 (2015.01)

CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 35/12 (2013.01); A61K 35/50 (2013.01); A61K 35/51 (2013.01); A61P 25/28 (2018.01); C12N 5/0665 (2013.01); C12N 2501/734 (2013.01)]

4 Claims

1. A method of treating a subject suffering from neonatal hypoxic ischemic encephalopathy (HIE), comprising;

treating mesenchymal stem cells derived from umbilical cord or umbilical cord blood with 50 units/mL of thrombin for 6 hours, and

administering the thrombin-treated mesenchymal stem cells into the subject,

wherein the subject suffering from HIE is treated by therapeutic hypothermia prior to the administering the thrombin-treated mesenchymal stem cells, and wherein said thrombin-treated mesenchymal stem cells are administered into a cerebral ventricle or blood vessel.